New drug duo shows promise for rare, deadly thyroid cancer
NCT ID NCT04171622
First seen Feb 18, 2026 · Last updated May 17, 2026 · Updated 12 times
Summary
This study tests a combination of two drugs, lenvatinib and pembrolizumab, in 25 people with advanced anaplastic thyroid cancer that cannot be surgically removed. The goal is to see if this treatment can shrink tumors and help patients live longer. Lenvatinib blocks enzymes that help cancer grow, while pembrolizumab boosts the immune system to attack cancer cells.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for THYROID GLAND SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.